AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19455340 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 200
Study 19455340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT)
Number of subjects: 200
Study 17185119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 40
Study 17185119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and Ibuprofen
Number of subjects: 40
Study 17185119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15379308 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocline (2% minocycline hydrochloride ointment)
Number of subjects: 11
Study 15379308 — intervention group
Group type: COMPARATOR
Intervention: Yakang (local metronidazole)
Number of subjects: 11
Study 11179058 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided breathing
Number of subjects: 39
Study 11179058 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 39
Study 11179058 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-guided breathing (increasing rates from 9 to 20 breaths/min)
Number of subjects: 39
Study 9771304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg kg‐1
Number of subjects: 48
Study 9771304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8160137 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (1 x 10(6) IU, once a week, i.m. for 2 months)
Number of subjects: 30
Study 29752027 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting-wide positive behaviour support (SWPBS)
Number of subjects: 24
Study 29752027 — intervention group
Group type: COMPARATOR
Intervention: Control group (individualized PBS access)
Number of subjects: 24
Study 27766453 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 707
Study 24835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert vigilant attention task with EEG monitoring
Number of subjects: 12
Study 24835495 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG activity in the α-frequency range (8-14 Hz)
Number of subjects: 12
Study 24835495 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 event-related component
Number of subjects: 12
Study 21868176 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 678
Study 21868176 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 678
Study 21868176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 678
Study 20189754 — intervention group
Group type: EXPERIMENTAL
Intervention: MET hospitals
Number of subjects: 0
Study 20189754 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 0
Study 18332472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg/d orally)
Number of subjects: 1598
Study 18332472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study 16567978 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV, Hib/HepB, and DTaP concomitantly
Number of subjects: 1915
Study 16567978 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV followed by Hib/HepB and DTaP 42 days later
Number of subjects: 1915
Study 16567978 — intervention group
Group type: COMPARATOR
Intervention: MMR and varicella vaccine followed by Hib/HepB and DTaP 42 days later
Number of subjects: 1915
Study 14562776 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally intravenous anaesthesia (propofol and remifentanil)
Number of subjects: 53
Study 14562776 — intervention group
Group type: COMPARATOR
Intervention: Mixed anaesthesia (isoflurane and fentanyl)
Number of subjects: 53
Study 10801250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.6 mg
Number of subjects: 9
Study 10801250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg
Number of subjects: 9
Study 10801250 — intervention group
Group type: COMPARATOR
Intervention: Lactate capsule (control)
Number of subjects: 9
Study 8721077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil (RIPM-AC)
Number of subjects: 208
Study 8721077 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam hexetil (CTM-HE)
Number of subjects: 208
Study 1558072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 74
Study 1558072 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 74
Study 3912190 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg orally
Number of subjects: 12
Study 3912190 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 12
Study 3912190 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly stroke patients
Number of subjects: 12
Study 3912190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (elderly stroke patients and healthy controls)
Number of subjects: 12
Study 3912190 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations based on mean data
Number of subjects: 12
Study 31314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (combination prevention intervention with universal antiretroviral therapy [ART])
Number of subjects: 48301
Study 31314965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (prevention intervention with ART provided according to local guidelines)
Number of subjects: 48301
Study 31314965 — intervention group
Group type: COMPARATOR
Intervention: Group C (standard care)
Number of subjects: 48301
Study 29850026 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Choices intervention (student needs survey, SHPC, classroom curriculum, student-led marketing, parent information, review of services)
Number of subjects: 6
Study 29850026 — intervention group
Group type: COMPARATOR
Intervention: Control group (two schools without the Positive Choices intervention)
Number of subjects: 6
Study 26897656 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM intervention (multi-session gender-equity focused family planning program)
Number of subjects: 1081
Study 24724863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions at counts of fewer than 10 × 10(9) /L
Number of subjects: 600
Study 24724863 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 600
Study 22607479 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler SMART™), starting dose 160 mg/4.5 mg two inhalations twice daily plus as-needed inhalations
Number of subjects: 404
Study 22607479 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone propionate (Seretide Diskus), starting dose 50 mg/250 mg bid plus salbutamol as needed
Number of subjects: 404
Study 20819525 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin administration (group B)
Number of subjects: 40
Study 20819525 — intervention group
Group type: COMPARATOR
Intervention: No somatostatin (group A)
Number of subjects: 40
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthma group
Number of subjects: 151
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups divided by asthma severity
Number of subjects: 151
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups divided according to bronchial hyperresponsiveness
Number of subjects: 151
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: EDN and PC(20) correlation
Number of subjects: 151
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP and PC(20) correlation
Number of subjects: 151
Study 17393238 — intervention group
Group type: EXPERIMENTAL
Intervention: EDN and ECP correlation
Number of subjects: 151
Study 15763644 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide pamoate and tamoxifen
Number of subjects: 150
Study 15763644 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen monotherapy
Number of subjects: 150
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 907
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 907
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination montelukast 10 mg and loratadine 10 mg
Number of subjects: 907
Study 12086367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs Loratadine alone
Number of subjects: 907
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs Placebo
Number of subjects: 907
Study 12086367 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast/loratadine vs each therapy alone
Number of subjects: 907
Study 9793700 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 1 mg
Number of subjects: 19
Study 9793700 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 5 mg
Number of subjects: 19
Study 9793700 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. naratriptan 10 mg
Number of subjects: 19
Study 9793700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7629756 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms Atrial natriuretic hormone (ANH)
Number of subjects: 12
Study 7629756 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IU arginine vasopressin (AVP)
Number of subjects: 12
Study 7629756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2117784 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (PaCO2 32-48 mm Hg)
Number of subjects: 25
Study 2117784 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (PaCO2 49-72 mm Hg)
Number of subjects: 25
Study 351073 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg on two consecutive days each week for six months)
Number of subjects: 99
Study 351073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to levamisole)
Number of subjects: 99
Study 31130273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with ropivacaine 0.5%, 20 ml
Number of subjects: 104
Study 31130273 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA) with ropivacaine 0.5%, 20 ml
Number of subjects: 104
Study 28708930 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT)
Number of subjects: 63
Study 24828126 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Hope Box (VHB) smartphone app
Number of subjects: 0
Study 24828126 — intervention group
Group type: COMPARATOR
Intervention: Conventional hope box integrated into VA behavioral health treatment
Number of subjects: 0
Study 22899402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 155
Study 22899402 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacologic treatment
Number of subjects: 155
Study 21106046 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine twice daily (BID)
Number of subjects: 37
Study 21106046 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine three times daily (TID)
Number of subjects: 37
Study 21106046 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine TID
Number of subjects: 37
Study 21106046 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine BID
Number of subjects: 37
Study 21106046 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine BID and TID
Number of subjects: 37
Study 21106046 — intervention group
Group type: COMPARATOR
Intervention: Open adherence monitoring
Number of subjects: 37
Study 19765430 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (2 doses)
Number of subjects: 43
Study 19765430 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (5 doses)
Number of subjects: 43
Study 19765430 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapies)
Number of subjects: 43
Study 16751166 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 60
Study 16751166 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular hylan G-F 20
Number of subjects: 60
Study 14631226 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bypass (hepaticojejunostomy and retrocolic gastrojejunostomy)
Number of subjects: 70
Study 14631226 — intervention group
Group type: COMPARATOR
Intervention: Single bypass (hepaticojejunostomy)
Number of subjects: 70
Study 11063767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg in 50 mL saline, warmed to 37 degrees C)
Number of subjects: 30
Study 11063767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30
Study 11063767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL distilled water in 50 mL saline)
Number of subjects: 30
Study 9093709 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-fluorouracil and levamisole)
Number of subjects: 95
Study 9093709 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 95
Study 9093709 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 95
Study 9093709 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 95
Study 8096373 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (two daily doses)
Number of subjects: 1075
Study 8096373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 3532335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (1 MU/m2) subcutaneous (SC) treatment 5 days per week, every other week, for eight weeks
Number of subjects: 60
Study 3532335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (50 MU/m2) intravenous (IV) treatment 5 days per week, every other week, for eight weeks
Number of subjects: 60
Study 3532335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (30 MU/m2) intravenous (IV) treatment three times per week for eight weeks
Number of subjects: 60
Study 3532335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of alpha interferon and chemotherapeutic agents (VP-16 and vinblastine)
Number of subjects: 60
Study 31206652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early UST (after uterine closure; n=24)
Number of subjects: 45
Study 31206652 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed UST (after skin closure; n=21)
Number of subjects: 45
Study 29295269 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centered design alerts
Number of subjects: 0
Study 29295269 — intervention group
Group type: COMPARATOR
Intervention: Traditional alerts
Number of subjects: 0
Study 25817062 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 132
Study 25817062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 132
Study 25817062 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study 23020840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive continuous passive motion for more than six hours per day
Number of subjects: 107
Study 23020840 — intervention group
Group type: COMPARATOR
Intervention: Basic rehabilitation protocols (Control group)
Number of subjects: 107
Study 21677649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-elicited responses to alcohol taste cues
Number of subjects: 326
Study 21677649 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD severity
Number of subjects: 326
Study 19059736 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom‐Centered (CC) intervention
Number of subjects: 563
Study 19059736 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood
Number of subjects: 563
Study 19059736 — intervention group
Group type: COMPARATOR
Intervention: Family‐School Partnership (FSP) intervention
Number of subjects: 563
Study 16567604 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 528
Study 12723461 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ 67657 (10 mg/kg)
Number of subjects: 0
Study 12723461 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ 67657 (20 mg/kg)
Number of subjects: 0
Study 12723461 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ 67657 (0.25-30 mg/kg)
Number of subjects: 0
Study 12723461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11730394 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d)
Number of subjects: 222
Study 11730394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 11730394 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who did not receive lipid‐lowering medication
Number of subjects: 222
Study 11730394 — intervention group
Group type: COMPARATOR
Intervention: Placebo among women who did not receive lipid‐lowering medication
Number of subjects: 222
Study 11730394 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol (1 mg/d) among women who took lipid‐lowering medication
Number of subjects: 222
Study 11730394 — intervention group
Group type: COMPARATOR
Intervention: Placebo among women who took lipid‐lowering medication
Number of subjects: 222
Study 9213324 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 8 courses
Number of subjects: 28
Study 9213324 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Number of subjects: 28
Study 9213324 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) + Doxorubicin (50 mg/m2) + Cyclophosphamide (500 mg/m2) for 4 to 6 courses with G-CSF (filgrastim) followed by high-dose chemotherapy with autologous peripheral blood stem-cell transplantation
Number of subjects: 28
Study 7970504 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/day
Number of subjects: 271
Study 7970504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 2455105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg
Number of subjects: 12
Study 2455105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, 20 mg
Number of subjects: 12
Study 2455105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Lisinopril combination
Number of subjects: 12
Study 2455105 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 29549005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplement group (beetroot juice)
Number of subjects: 25
Study 29549005 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (black currant juice)
Number of subjects: 25
Study 28288974 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20702
Study 28288974 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus folic acid
Number of subjects: 20702
Study 25684765 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab (IFX) therapy
Number of subjects: 0
Study 25684765 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg or 10 mg/kg infliximab (IFX) therapy
Number of subjects: 0
Study 23160180 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) intake
Number of subjects: 310
Study 22125980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal Z-type lengthening of transverse carpal ligament
Number of subjects: 68
Study 22125980 — intervention group
Group type: COMPARATOR
Intervention: Conventional open approach surgery
Number of subjects: 68
Study 19246785 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive polyurethane foam dressing
Number of subjects: 36
Study 16290043 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 101
Study 16290043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 101
Study 16290043 — intervention group
Group type: COMPARATOR
Intervention: Isotonic Saline
Number of subjects: 101
Study 15518675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise deprivation for 1 week
Number of subjects: 18
Study 15518675 — intervention group
Group type: COMPARATOR
Intervention: Baseline measures of HPA axis, immune, and autonomic function
Number of subjects: 18
Study 11083571 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraPulse CO2 laser
Number of subjects: 20
Study 11083571 — intervention group
Group type: COMPARATOR
Intervention: Dermabrasion
Number of subjects: 20
Study 9122733 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD regimen (cisplatin, vinblastine, and dacarbazine) followed by rIFN‐α and rIL‐2
Number of subjects: 62
Study 8301881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5
Study 8301881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (300 mg/die)
Number of subjects: 11
Study 3301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (50 mg/die)
Number of subjects: 11
Study 3301505 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (400 mg/die)
Number of subjects: 11
Study 3301505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29911074 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day miltefosine monotherapy
Number of subjects: 497
Study 29911074 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB)
Number of subjects: 497
Study 29911074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (L-AMB)
Number of subjects: 497
Study 29911074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin concentration increase
Number of subjects: 497
Study 27111642 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐Spec™ Monitoring System (pulse spectroscopy)
Number of subjects: 19
Study 25142196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) combined with antidepressant medication (ADM)
Number of subjects: 452